Ascendis Pharma A/S (NASDAQ:ASND) Rating Lowered to “Sell” at StockNews.com

StockNews.com cut shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a sell rating in a research report report published on Tuesday morning.

ASND has been the topic of a number of other reports. Citigroup increased their price target on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Evercore ISI lifted their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 17th. The Goldman Sachs Group boosted their price target on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Bank of America raised their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Finally, Wedbush upgraded Ascendis Pharma A/S to a “strong-buy” rating in a report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and an average price target of $195.92.

Ascendis Pharma A/S Stock Down 1.4 %

ASND stock opened at $124.28 on Tuesday. Ascendis Pharma A/S has a twelve month low of $90.13 and a twelve month high of $161.00. The company has a market cap of $7.54 billion, a P/E ratio of -13.35 and a beta of 0.66. The business’s fifty day moving average is $132.15 and its 200-day moving average is $132.80.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. Research analysts anticipate that Ascendis Pharma A/S will post -7.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors have recently bought and sold shares of the company. Signaturefd LLC lifted its position in shares of Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares in the last quarter. Bessemer Group Inc. lifted its position in Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after buying an additional 332 shares in the last quarter. Pursue Wealth Partners LLC bought a new stake in Ascendis Pharma A/S during the 3rd quarter worth about $217,000. Searle & CO. acquired a new position in shares of Ascendis Pharma A/S during the 2nd quarter worth about $205,000. Finally, Rhumbline Advisers grew its holdings in shares of Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 143 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.